Zydus Cadila has announced the launch of its Forglyn formoterol fumarate / glycopyrrolate MDI for the treatment of COPD India. According to Zydus Cadila, the inhaler, which was developed at the company's Pharmaceutical Technology Center, will cost ₹495 (~$7) per pack. Cadila Healthcare Managing Director Sharvil Patel commented, "Our focus has always been on helping … [Read more...] about Zydus Cadila launches Forglyn formoterol / glycopyrrolate MDI in India
News
Revelation Biosciences announces Phase 1 trial of its intranasal PHAD
Revelation Biosciences announced that the Australian Therapeutic Goods Administration has okayed a Phase 1 clinical study of the company's REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), which Revelation is developing for the treatment of COVID‑19. According to the company's web site, "REVTx-99 acts by stimulating the innate immune response via … [Read more...] about Revelation Biosciences announces Phase 1 trial of its intranasal PHAD
Proveris partners with Australian universities on new method of characterizing pharmaceutical aerosols
Aerosol characterization specialist Proveris Scientific has announced that it is working with the University of Sydney and Macquarie University to develop a new method of measuring the surface area of pharmaceutical aerosol particles using optical tomography technology. The project is funded by the Australian Research Council Linkage Program and will be led by Hak-Kim … [Read more...] about Proveris partners with Australian universities on new method of characterizing pharmaceutical aerosols
Irish consortium to develop inhaled exosomes therapy for ARDS, COPD
A consortium formed by Irish biotech OmniSpirant, nebulizer maker Aerogen, and the National University of Ireland Galway has received a €11.6 million grant from Ireland's Disruptive Technologies Innovation Fund for development of OS002, an inhaled exosomes therapy for the treatment of acute respiratory distress syndrome (ARDS) as well as for COPD. The 3-year project … [Read more...] about Irish consortium to develop inhaled exosomes therapy for ARDS, COPD
Teva launches Aermony RespiClick in Canada
Teva Canada has launched the Aermony RespiClick fluticasone propionate DPI for the treatment of asthma, the company said. The inhaler will be available in 55 mcg, 113 mcg, and 232 mcg per actuation versions. According to the Health Canada web site, Aermony Respiclick was approved in 2017, the same year that ArmonAir Resplick fluticasone propionate was approved in … [Read more...] about Teva launches Aermony RespiClick in Canada
Starpharma raises A$45 million to be used in part for development of astodrimer sodium nasal spray for COVID-19
Starpharma said that it has raised A$45 million and expects to raise another A$5 million from Australian and international investors, with proceeds to be used for development of its SPL7013 astodrimer sodium nasal spray for the treatment of COVID-19 as well as for other candidates. The company recently announced that the nasal spray inactivated almost 100% of … [Read more...] about Starpharma raises A$45 million to be used in part for development of astodrimer sodium nasal spray for COVID-19
AZTherapies raises $33.6 million as Phase 3 trial of its inhaled Alzheimer’s therapy nears completion
AZTherapies said that it has closed a $33.6 million Series C-1 financing that will fund regulatory and pre-commercial activities related to the company's ALZT-OP1 inhaled cromolyn/oral ibuprofen for Alzheimer’s disease and for development of other candidates. The financing round was led by Duopharma Biotech Berhad. In October 2019, AZTherapies announced that it had … [Read more...] about AZTherapies raises $33.6 million as Phase 3 trial of its inhaled Alzheimer’s therapy nears completion
Studies show spray dried niclosamide/hLYS formulation has strong activity against SARS-CoV-2
Researchers from the University of Texas at Austin and Chungnam National University have published in vitro and in vivo data demonstrating that a dry powder formulation of niclosamide that includes human lysozyme (hLYS) as a carrier exhibits potent activity against both the MERS-CoV and SARS-CoV-2 viruses. The article is available as a preprint on BioRxiv and is … [Read more...] about Studies show spray dried niclosamide/hLYS formulation has strong activity against SARS-CoV-2
Preclinical testing demonstrates that Ena Respiratory’s intranasal antiviral reduces replication of SARS-CoV-2
Ena Respiratory (formerly Innavac) said that its INNA-051 pegylated TLR2/6 agonist nasal spray reduced replication of the SARS-CoV-2 virus in a ferret model by up to 96% in a study conducted by researchers at Public Health England. The company also announced that it has raised AU$11.7 million in Series A financing for a clinical trial that could begin by early 2021 … [Read more...] about Preclinical testing demonstrates that Ena Respiratory’s intranasal antiviral reduces replication of SARS-CoV-2
Aerami CEO Anne Whitaker steps down from Vectura board of directors
Inhalation CDMO Vectura has announced the resignation of Aerami CEO Anne Whitaker from Vectura's board of directors "in light of potential conflicts that could arise in the future as a result of her role of Chief Executive Officer at Aerami Therapeutics." In June 2020, Vectura and Aerami announced a partnership agreement for development of inhaled imatinib (VR325) … [Read more...] about Aerami CEO Anne Whitaker steps down from Vectura board of directors